List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1404740/publications.pdf Version: 2024-02-01



ΙΠΑΝ D CAÃ+ETE

#	Article	IF	CITATIONS
1	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 700.1-712.	0.5	609
2	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Annals of the Rheumatic Diseases, 2014, 73, 1012-1019.	0.5	314
3	Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. Nature Communications, 2020, 11, 1995.	5.8	253
4	Interleukinâ€17–positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis and Rheumatism, 2012, 64, 99-109.	6.7	244
5	Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nature Medicine, 2017, 23, 938-944.	15.2	223
6	Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Research, 2005, 7, R569.	2.0	218
7	Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmunity Reviews, 2020, 19, 102429.	2.5	197
8	Synovial tissue research: a state-of-the-art review. Nature Reviews Rheumatology, 2017, 13, 463-475.	3.5	175
9	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet, The, 2021, 397, 305-317.	6.3	145
10	Antiangiogenic effects of anti-tumor necrosis factor α therapy with infliximab in psoriatic arthritis. Arthritis and Rheumatism, 2004, 50, 1636-1641.	6.7	137
11	Ectopic lymphoid neogenesis in psoriatic arthritis. Annals of the Rheumatic Diseases, 2007, 66, 720-726.	0.5	121
12	Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. Nature Medicine, 2022, 28, 1256-1268.	15.2	105
13	B Lymphocyte Autoimmunity in Rheumatoid Synovitis Is Independent of Ectopic Lymphoid Neogenesis. Journal of Immunology, 2008, 181, 785-794.	0.4	102
14	Urine metabolome profiling of immune-mediated inflammatory diseases. BMC Medicine, 2016, 14, 133.	2.3	97
15	Anakinra for the treatment of rheumatoid arthritis: a safety evaluation. Expert Opinion on Drug Safety, 2018, 17, 727-732.	1.0	92
16	Risk variants for psoriasis vulgaris in a large case–control collection and association with clinical subphenotypes. Human Molecular Genetics, 2012, 21, 4549-4557.	1.4	79
17	Immature Blood Vessels in Rheumatoid Synovium Are Selectively Depleted in Response to Anti-TNF Therapy. PLoS ONE, 2009, 4, e8131.	1.1	76
18	Human mast cells capture, store, and release bioactive, exogenous IL-17A. Journal of Leukocyte Biology, 2016, 100, 453-462.	1.5	69

#	Article	IF	CITATIONS
19	Synovial fibroblast hyperplasia in rheumatoid arthritis: Clinicopathologic correlations and partial reversal by anti–tumor necrosis factor therapy. Arthritis and Rheumatism, 2011, 63, 2575-2583.	6.7	66
20	Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study. Arthritis Research and Therapy, 2017, 19, 72.	1.6	64
21	An unexpectedly high frequency of <i>MEFV</i> mutations in patients with anti–citrullinated protein antibody–negative palindromic rheumatism. Arthritis and Rheumatism, 2007, 56, 2784-2788.	6.7	63
22	Notch-regulated miR-223 targets the aryl hydrocarbon receptor pathway and increases cytokine production in macrophages from rheumatoid arthritis patients. Scientific Reports, 2016, 6, 20223.	1.6	63
23	Palindromic rheumatism and other relapsing arthritis. Best Practice and Research in Clinical Rheumatology, 2004, 18, 647-661.	1.4	61
24	GWAS replication study confirms the association of <i>PDE3A–SLCO1C1</i> with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics, 2013, 14, 727-734.	0.6	61
25	Diagnostic usefulness of synovial vascular morphology in chronic arthritis. A systematic survey of 100 cases. Seminars in Arthritis and Rheumatism, 2003, 32, 378-387.	1.6	60
26	Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Research and Therapy, 2012, 14, R93.	1.6	60
27	Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. Rheumatology, 2015, 54, 915-926.	0.9	60
28	Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review. Rheumatology, 2016, 55, 1188-1194.	0.9	60
29	Diseaseâ€specific and inflammationâ€independent stromal alterations in spondylarthritis synovitis. Arthritis and Rheumatism, 2013, 65, 174-185.	6.7	59
30	Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. Annals of the Rheumatic Diseases, 2019, 78, 201-208.	0.5	59
31	Determinants of Patientâ€₽hysician Discordance in Global Assessment in Psoriatic Arthritis: A Multicenter European Study. Arthritis Care and Research, 2017, 69, 1606-1611.	1.5	58
32	Senescent synovial fibroblasts accumulate prematurely in rheumatoid arthritis tissues and display an enhanced inflammatory phenotype. Immunity and Ageing, 2019, 16, 29.	1.8	54
33	Identification and characterization of a novel spliced variant that encodes human soluble tumor necrosis factor receptor 2. International Immunology, 2004, 16, 169-177.	1.8	53
34	Hif-1α Knockdown Reduces Glycolytic Metabolism and Induces Cell Death of Human Synovial Fibroblasts Under Normoxic Conditions. Scientific Reports, 2017, 7, 3644.	1.6	53
35	Cutaneous Adverse Events During Treatment of Chronic Inflammatory Rheumatic Conditions With Tumor Necrosis Factor Antagonists: Study Using the Spanish Registry of Adverse Events of Biological Therapies in Rheumatic Diseases. Arthritis Care and Research, 2013, 65, 2024-2031.	1.5	52
36	Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease. Annals of the Rheumatic Diseases, 2020, 79, 587-594.	0.5	52

#	Article	IF	CITATIONS
37	Distinct synovial immunopathology in Behçet disease and psoriatic arthritis. Arthritis Research and Therapy, 2009, 11, R17.	1.6	51
38	Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitis. Arthritis Research and Therapy, 2015, 17, 173.	1.6	51
39	Transcription factor Fra-1 targets arginase-1 to enhance macrophage-mediated inflammation in arthritis. Journal of Clinical Investigation, 2019, 129, 2669-2684.	3.9	51
40	The clinical significance of amyloid fat deposits in rheumatoid arthritis: A systematic long-term followup study using abdominal fat aspiration. Arthritis and Rheumatism, 2001, 44, 66-72.	6.7	50
41	Patients with rheumatoid arthritis in clinical remission and ultrasound-defined active synovitis exhibit higher disease activity and increased serum levels of angiogenic biomarkers. Arthritis Research and Therapy, 2014, 16, R5.	1.6	50
42	Multidisciplinary dermatology–rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review. Rheumatology International, 2016, 36, 221-229.	1.5	48
43	Fatigue in psoriatic arthritis–Âa cross-sectional study of 246Âpatients from 13Âcountries. Joint Bone Spine, 2016, 83, 439-443.	0.8	47
44	Inflammatory cytokines shape a changing DNA methylome in monocytes mirroring disease activity in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, 1505-1516.	0.5	47
45	Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. Annals of the Rheumatic Diseases, 2019, 78, 355-364.	0.5	44
46	Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis. Annals of the Rheumatic Diseases, 2021, 80, 451-468.	0.5	43
47	Serum Calprotectin Versus Acuteâ€Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors. Arthritis Care and Research, 2016, 68, 899-906.	1.5	42
48	Efficacy and Safety of Anti–Interleukinâ€20 Monoclonal Antibody in Patients With Rheumatoid Arthritis: A Randomized Phase IIa Trial. Arthritis and Rheumatology, 2015, 67, 1438-1448.	2.9	39
49	Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. Arthritis Research and Therapy, 2016, 18, 160.	1.6	39
50	Determinants of Patientâ€Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association WithSex in 458 Patients From Fourteen Countries. Arthritis Care and Research, 2020, 72, 1772-1779.	1.5	39
51	Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis. Arthritis Research and Therapy, 2009, 11, R135.	1.6	38
52	Effects of Smoking on Disease Activity and Radiographic Progression in Early Rheumatoid Arthritis. Journal of Rheumatology, 2011, 38, 2536-2539.	1.0	38
53	Clinicopathological Correlations of Podoplanin (gp38) Expression in Rheumatoid Synovium and Its Potential Contribution to Fibroblast Platelet Crosstalk. PLoS ONE, 2014, 9, e99607.	1.1	38
54	Transcriptome analysis reveals specific changes in osteoarthritis synovial fibroblasts. Annals of the Rheumatic Diseases, 2012, 71, 275-280.	0.5	36

#	Article	IF	CITATIONS
55	Patient global assessment in psoriatic arthritis – what does it mean? An analysis of 223Âpatients from the Psoriatic arthritis impact of disease (PsAID) study. Joint Bone Spine, 2016, 83, 335-340.	0.8	35
56	Variation at FCGR2A and Functionally Related Genes Is Associated with the Response to Anti-TNF Therapy in Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0122088.	1.1	33
57	Immunopathologic characterization of ultrasound-defined synovitis in rheumatoid arthritis patients in clinical remission. Arthritis Research and Therapy, 2016, 18, 74.	1.6	33
58	B Cell Synovitis and Clinical Phenotypes in Rheumatoid Arthritis: Relationship to Disease Stages and Drug Exposure. Arthritis and Rheumatology, 2020, 72, 714-725.	2.9	33
59	Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenetics and Genomics, 2014, 24, 238-245.	0.7	32
60	Recomendaciones de la Sociedad Española de ReumatologÃa sobre el tratamiento y uso de terapias sistémicas biológicas y no biológicas en artritis psoriásica. ReumatologÃa ClÃnica, 2018, 14, 254-268.	0.2	32
61	Palindromic Rheumatism with Positive Anticitrullinated Peptide/Protein Antibodies Is Not Synonymous with Rheumatoid Arthritis. A Longterm Followup Study. Journal of Rheumatology, 2012, 39, 1929-1933.	1.0	31
62	EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2021, 80, 1286-1298.	0.5	31
63	Safety profile of biological therapies for treating rheumatoid arthritis. Expert Opinion on Biological Therapy, 2017, 17, 1089-1103.	1.4	30
64	Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups. Arthritis Research and Therapy, 2018, 20, 265.	1.6	29
65	Morphea associated with the use of adalimumab: a case report and review of the literature. Modern Rheumatology, 2012, 22, 602-604.	0.9	28
66	Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study. Arthritis Research and Therapy, 2018, 20, 275.	1.6	28
67	Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Research and Therapy, 2020, 22, 14.	1.6	27
68	Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. Rheumatology, 2015, 54, kev251.	0.9	26
69	Lack of validation of genetic variants associated with anti–tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. Arthritis Research and Therapy, 2014, 16, R66.	1.6	25
70	Histologic evidence that mast cells contribute to local tissue inflammation in peripheral spondyloarthritis by regulating interleukin-17A content. Rheumatology, 2019, 58, 617-627.	0.9	25
71	The link between obesity and psoriatic arthritis. Annals of the Rheumatic Diseases, 2012, 71, 1265-1266.	0.5	24
72	A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis. Frontiers in Immunology, 2019, 10, 1459.	2.2	24

#	Article	IF	CITATIONS
73	Association of intermittent hydrarthrosis withMEFV gene mutations. Arthritis and Rheumatism, 2006, 54, 2334-2335.	6.7	23
74	Reducción de dosis de terapias biológicas en enfermedades reumáticas: análisis descriptivo de 153 pacientes en condiciones de práctica clÃnica. ReumatologÃa ClÃnica, 2014, 10, 10-16.	0.2	22
75	Psoriatic Synovitis: Singularity and Potential Clinical Implications. Frontiers in Medicine, 2019, 6, 14.	1.2	20
76	Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. RMD Open, 2020, 6, e001170.	1.8	20
77	Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis. Journal of Rheumatology, 2019, 46, 710-715.	1.0	19
78	Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept. PLoS ONE, 2019, 14, e0213073.	1.1	19
79	The Impact of Comorbidity on Patient-Reported Outcomes in Psoriatic Arthritis: A Systematic Literature Review. Rheumatology and Therapy, 2020, 7, 237-257.	1.1	19
80	A deletion atADAMTS9-MAGI1locus is associated with psoriatic arthritis risk. Annals of the Rheumatic Diseases, 2015, 74, 1875-1881.	0.5	18
81	CD271+ stromal cells expand in arthritic synovium and exhibit a proinflammatory phenotype. Arthritis Research and Therapy, 2016, 18, 66.	1.6	18
82	Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study. Rheumatology and Therapy, 2020, 7, 825-836.	1.1	18
83	Clinical significance of high levels of soluble tumour necrosis factor-Â receptor-2 produced by alternative splicing in rheumatoid arthritis: a longitudinal prospective cohort study. Rheumatology, 2011, 50, 721-728.	0.9	17
84	Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up. Seminars in Arthritis and Rheumatism, 2017, 47, 303-309.	1.6	17
85	Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis. Arthritis Research and Therapy, 2017, 19, 141.	1.6	17
86	GM-CSF Expression and Macrophage Polarization in Joints of Undifferentiated Arthritis Patients Evolving to Rheumatoid Arthritis or Psoriatic Arthritis. Frontiers in Immunology, 2020, 11, 613975.	2.2	17
87	Is There Subclinical Synovitis in Patients with Palindromic Rheumatism in the Intercritical Period? A Clinical and Ultrasonographic Study According to Anticitrullinated Protein Antibody Status. Journal of Rheumatology, 2014, 41, 1650-1655.	1.0	16
88	Prediction of the Progression of Undifferentiated Arthritis to Rheumatoid Arthritis Using DNA Methylation Profiling. Arthritis and Rheumatology, 2021, 73, 2229-2239.	2.9	16
89	Differential Antigen-presenting B Cell Phenotypes from Synovial Microenvironment of Patients with Rheumatoid and Psoriatic Arthritis. Journal of Rheumatology, 2015, 42, 1825-1834.	1.0	15
90	The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Expert Opinion on Drug Safety, 2016, 15, 613-624.	1.0	15

#	Article	IF	CITATIONS
91	Identification of a distinct lipidomic profile in the osteoarthritic synovial membrane by mass spectrometry imaging. Osteoarthritis and Cartilage, 2021, 29, 750-761.	0.6	15
92	A genome-wide association study identifies <i>SLC8A3</i> as a susceptibility locus for ACPA-positive rheumatoid arthritis. Rheumatology, 2016, 55, 1106-1111.	0.9	14
93	Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. Joint Bone Spine, 2020, 87, 449-454.	0.8	14
94	Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. PLoS ONE, 2018, 13, e0196793.	1.1	13
95	Palindromic rheumatism: Evidence of four subtypes of palindromic-like arthritis based in either MEFV or rheumatoid factor/ACPA status. Joint Bone Spine, 2021, 88, 105235.	0.8	13
96	Macroscopic features of knee synovitis in early untreated Behçet disease and psoriatic arthritis. Clinical Rheumatology, 2009, 28, 1053-1057.	1.0	12
97	Biologic Therapy in Rheumatoid Arthritis. Current Topics in Medicinal Chemistry, 2013, 13, 752-759.	1.0	12
98	EULAR points to consider for minimal reporting requirements in synovial tissue research in rheumatology. Annals of the Rheumatic Diseases, 2022, 81, 1640-1646.	0.5	12
99	Variation at interleukin-6 receptor gene is associated to joint damage in rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 242.	1.6	11
100	Expert Consensus on a Set of Outcomes to Assess the Effectiveness of Biologic Treatment in Psoriatic Arthritis: The MERECES Study. Journal of Rheumatology, 2020, 47, 1637-1643.	1.0	11
101	The synovial and blood monocyte DNA methylomes mirror prognosis, evolution, and treatment in early arthritis. JCI Insight, 2022, 7, .	2.3	11
102	IL6/sIL6R regulates TNFα-inflammatory response in synovial fibroblasts through modulation of transcriptional and post-transcriptional mechanisms. BMC Molecular and Cell Biology, 2020, 21, 74.	1.0	10
103	Palindromic Rheumatism: Just a Pre-rheumatoid Stage or Something Else?. Frontiers in Medicine, 2021, 8, 657983.	1.2	10
104	Update on Cardiovascular Risk and Obesity in Psoriatic Arthritis. Frontiers in Medicine, 2021, 8, 742713.	1.2	10
105	Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission. Clinical and Experimental Rheumatology, 2017, 35, 74-79.	0.4	10
106	Minimal disease activity (MDA) in patients with recent-onset psoriatic arthritis: predictive model based on machine learning. Arthritis Research and Therapy, 2022, 24, .	1.6	10
107	Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study. Arthritis Research and Therapy, 2015, 17, 63.	1.6	9
108	The Transcriptional Coactivator Bob1 Is Associated With Pathologic B Cell Responses in Autoimmune Tissue Inflammation. Arthritis and Rheumatology, 2017, 69, 750-762.	2.9	9

#	Article	IF	CITATIONS
109	Rheumatoid Arthritis Initiating as Palindromic Rheumatism: A Distinct Clinical Phenotype?. Journal of Rheumatology, 2020, 47, 652-657.	1.0	9
110	Lower peripheral helper T cell levels in the synovium are associated with a better response to anti-TNF therapy in rheumatoid arthritis. Arthritis Research and Therapy, 2020, 22, 196.	1.6	9
111	Definition of Remission and Disease Activity Assessment in Psoriatic Arthritis: Evidence and Expert-Based Recommendations. ReumatologÃa ClÃnica, 2021, 17, 343-350.	0.2	9
112	Palindromic rheumatism: a unique and enigmatic entity with a complex relationship with rheumatoid arthritis. Expert Review of Clinical Immunology, 2021, 17, 375-384.	1.3	9
113	Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association?. Clinical Rheumatology, 2018, 37, 661-666.	1.0	8
114	Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2097813.	1.2	8
115	Biomarkers for treatment change and radiographic progression in patients with rheumatoid arthritis in remission: a 5 year follow-up study. Rheumatology, 2021, 60, 667-674.	0.9	8
116	Synovial Immunohistological Biomarkers of the Classification of Undifferentiated Arthritis Evolving to Rheumatoid or Psoriatic Arthritis. Frontiers in Medicine, 2021, 8, 656667.	1.2	8
117	Eficacia de los fármacos antirreumáticos modificadores de la enfermedad sintéticos en artritis psoriásica: una revisión sistemática. ReumatologÃa ClÃnica, 2018, 14, 81-89.	0.2	7
118	Registro Español de Artritis Psoriásica de Reciente Comienzo (estudio REAPSER). Objetivos y metodologĂa. ReumatologÃa ClÃnica, 2019, 15, 252-257.	0.2	7
119	Identification of <i>IRX1</i> as a Risk Locus for Rheumatoid Factor Positivity in Rheumatoid Arthritis in a Genomeâ€Wide Association Study. Arthritis and Rheumatology, 2016, 68, 1384-1391.	2.9	6
120	Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study. Arthritis Research and Therapy, 2020, 22, 82.	1.6	6
121	Ankylosing Spondylitis without Axial Progression: Analysis of Associated Factors. Journal of Rheumatology, 2014, 41, 2409-2412.	1.0	5
122	Recomendaciones sobre el uso de metotrexato en pacientes con artritis psoriásica. ReumatologÃa ClÃnica, 2018, 14, 183-190.	0.2	5
123	Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study. European Journal of Clinical Nutrition, 2021, 75, 1368-1382.	1.3	5
124	Whatâ€,influences patients' opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study. Rheumatology, 2021, 60, 5292-5299.	0.9	4
125	Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries. RMD Open, 2022, 8, e002031.	1.8	4
126	High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study. Diagnostics, 2022, 12, 182.	1.3	3

#	Article	IF	CITATIONS
127	THU0606â€PROLIFERATIVE GLOBULAR SYNOVITIS, A CHARACTERISTIC ULTRASONOGRAPHIC PATTERN OF SEROPOSITIVE RHEUMATOID ARTHRITIS. , 2019, , .		2
128	Determination of Soluble Tumor Necrosis Factor Receptor 2 Produced by Alternative Splicing. Methods in Molecular Biology, 2014, 1155, 187-199.	0.4	2
129	Proliferative synovitis, an ultrasound pattern associated with ACPA-positive patients and erosive disease in rheumatoid arthritis. Clinical and Experimental Rheumatology, 0, , .	0.4	2
130	Mast cells contribute to synovial inflammation in non-psoriatic and psoriatic spondyloarthritis. Annals of the Rheumatic Diseases, 2011, 70, A54-A55.	0.5	1
131	THU0683â€COVERAGE, PREDICTORS OF VACCINATION AND FREQUENCY OF SEVERE INFECTIONS DUE TO STREPTOCOCCUS PNEUMONIAE IN A COHORT OF PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS WITHIN AN EIGHTEEN-YEAR PERIOD. , 2019, , .		1
132	Comparable long-term outcomes between DAS28-ESR remission criteria and ACR/EULAR definitions in patients with established rheumatoid arthritis. Clinical Rheumatology, 2021, 40, 2665-2672.	1.0	1
133	Proliferative synovitis, an ultrasound pattern associated with ACPA-positive patients and erosive disease in rheumatoid arthritis. Clinical and Experimental Rheumatology, 2021, , .	0.4	1
134	A5.31â€The Role of BOB1 in Rheumnatoid Arthritis: Potential Implications for Autoimmunity. Annals of the Rheumatic Diseases, 2013, 72, A41.3-A42.	0.5	0
135	THU0218â€IDENTIFICATION, VERIFICATION AND VALIDATION OF NEW BIOMARKER CANDIDATES FOR MONITORING ACTIVITY IN PSORIATIC ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY DISEASES (IMIDS). , 2019, , .		0
136	AB0778â€IMPACT OF DISEASE IN A SPANISH POPULATION WITH PSORIATIC ARTHRITIS. , 2019, , .		0
137	AB0782â€SECUKINUMAB PROVIDES IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS, REGARDLESS OF THE TIME SINCE DIAGNOSIS: POOLED RESULTS FROM THE SECUKINUMAB PHASE 3 TRIAL PROGRAM. , 2019, , .		0
138	THU0068â€ANTI-CARBAMYLATED ANTIBODIES ARE ASSOCIATED WITH TOBACCO AND POOR OUTCOMES IN RHEUMATOID ARTHRITIS. , 2019, , .		0
139	Delayed soft tissue emphysema of the leg following arthroscopy of the knee. Medicina ClÃnica, 2021, 156, 476.	0.3	0
140	Definition of Remission and Disease Activity Assessment in Psoriatic Arthritis: Evidence and Expert-Based Recommendations. ReumatologÃa ClÃnica (English Edition), 2021, 17, 343-350.	0.2	0
141	Good clinimetric alignment between remission and a low impact of disease in patients with axial psoriatic arthritis. Clinical and Experimental Rheumatology, 2020, 38, 136-139.	0.4	О